start note buy
ep exclud amort intang asset acquisition-rel cost impair charg
headquart marlborough develop manufactur suppli premium diagnost product
medic imag system surgic product women around world fy compani gener
billion revenu adjust ebitda billion current oper five segment breast health
diagnost gyn surgic medic aesthet skelet health
januari announc preliminari first quarter result expect
compani guidanc compani expect report revenu million increas million
previou guidanc million
diagnost revenu expect decreas million million exclud blood busi
divestitur januari diagnost would increas million million breast health
revenu expect increas million million medic aesthet segment creat
march cynosur acquisit expect gener million revenu gyn surgic revenu
expect decreas million million skelet revenu expect remain
approxim flat million
passag us tax reform legisl expect tax rate rang
explain first quarter growth driver includ strength breast health molecular diagnost
intern busi tax reform increas profit provid opportun re-invest
previous provid fairli larg rang guidanc fy includ mid-singl digit organ revenu
growth organ growth defin total revenu less blood screen full year less cynosur
revenu expect increas billion billion gross margin continu
take hit blood screen divestitur annual adjust estim includ newli
guid tax rate increas estim cash ep
million except per share
compani data gabelli compani estim
despit deceler mammographi convers believ grow revenu billion
billion fiscal look beyond expect grow diagnost market
placement sale remain robust complement global opportun manag confid recent blood
screen divestitur cynosur integr underway medium-term growth driver includ cynosur new
product launch intern expans accret acquisit forecast ebitda billion
translat earn per share valu ebitda calcul fiscal pmv
per share recommend investor buy share
million except per share
current market discount pmv
after-tax payment buy option holder privat market valu
compani data gabelli compani estim
sara wojda research analyst prepar report herebi certifi view express report accur reflect analyst person
view subject compani secur research analyst receiv direct indirect compens
express specif recommend view report
public data octob buy rate
